EVX-020

News alerts, weekly reports and conference planners

Company:

Evexta Bio

Drug class:

KIF20A inhibitor

‹

›

over3years

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia (ASH 2022)

In the same experimental conditions, cytarabine (CYTA) had median IC50 of 207 nM (range 4-1580 nM)...Nevertheless, caspase inhibitors ZVAD-fmk and Emricasan partially rescued DIACC2010 cell death, although these inhibitors significantly rescued caspase activation induced by Venetoclax, a BCL-2 inhibitor triggering intrinsic apoptosis commonly used in AML treatment... Altogether, these results confirm the relevance of KIF20A-directed therapeutic approaches and support the development of DIACC2010 for the treatment of AML.

over 3 years ago

Preclinical • IO biomarker

GLI2 (GLI Family Zinc Finger 2) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • ANXA5 (Annexin A5) • KIF20A (Kinesin Family Member 20A)

Venclexta (venetoclax) • cytarabine • EVX-020